The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial

Gita Ramjee, Ariane van der Straten, Tsungai Chipato, Guy de Bruyn, Kelly Blanchard, Stephen Shiboski, Helen Cheng, Elizabeth Montgomery, Nancy Padian, MIRA team, Gita Ramjee, Ariane van der Straten, Tsungai Chipato, Guy de Bruyn, Kelly Blanchard, Stephen Shiboski, Helen Cheng, Elizabeth Montgomery, Nancy Padian, MIRA team

Abstract

Background: We evaluated the effectiveness of the Ortho All-Flex Diaphragm, lubricant gel (Replens) and condoms compared to condoms alone on the incidence of chlamydial and gonococcal infections in an open-label randomized controlled trial among women at risk of HIV/STI infections.

Methods: We randomized 5045 sexually-active women at three sites in Southern Africa. Participants who tested positive for curable STIs were treated prior to enrollment as per local guidelines. Women were followed quarterly and tested for Chlamydia trachomatis (CT) or Neisseria gonorrhoeae (GC) infection by nucleic-acid amplification testing (Roche Amplicor) using first-catch urine specimens. STIs detected at follow-up visits were treated. We compared the incidence of first infection after randomization between study arms in both intent-to-treat (ITT) and per-protocol populations.

Findings: Baseline demographic, behavioral and clinical characteristics were balanced across study arms. Nearly 80% of participants were under 35 years of age. Median follow-up time was 21 months and the retention rate was over 93%. There were 471 first chlamydia infections, 247 in the intervention arm and 224 in the control arm with an overall incidence of 6.2/100 woman-years (wy) (relative hazard (RH) 1.11, 95% Confidence Interval (CI): 0.93-1.33; p = 0.25) and 192 first gonococcal infections, 95 in the intervention arm and 97 in the control arm with an overall incidence of 2.4/100wy (RH 0.98, 95%CI: 0.74-1.30; p = 0.90). Per protocol results indicated that when diaphragm adherence was defined as "always use" since the last visit, there was a significant reduction in the incidence of GC infection among women randomized to the intervention arm (RH 0.61, 95%CI: 0.41-0.91, P = 0.02).

Interpretation: There was no difference by study arm in the rate of acquisition of CT or GC. However, our per-protocol results suggest that consistent use of the diaphragm may reduce acquisition of GC.

Trial registration: ClinicalTrials.gov NCT00121459.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. CONSORT Flow Diagram (CT/GC Trial…
Figure 1. CONSORT Flow Diagram (CT/GC Trial Profile).
Figure 2. Cumulative probability of CT infection…
Figure 2. Cumulative probability of CT infection (Kaplan-Meier estimates) by group.
Figure 3. Cumulative probability of GC infection…
Figure 3. Cumulative probability of GC infection (Kaplan-Meier estimates) by group.

References

    1. UNAIDS/WHO. UNAIDS AIDS Epidemic Update. 2007. Available: . Accessed 31 January 2008.
    1. Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, et al. The Value of Site Preparedness Studies for Future Implementation of Phase 2/IIb/III HIV Prevention Trials. Experience from the HPTN 055 Study. JAIDS. 2008;47:93–100.
    1. Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet. 2007;370:251–261.
    1. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, et al. SAVVY Vaginal Gel (C31G) for Prevention of HIV Infection: A Randomized Controlled Trial in Nigeria. PLoS One. 2008;3:e1474.
    1. Peterson L, Taylor D, Roddy R, Belai G, Phillips P, et al. Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial. PLoS Clinical Trials. 2007;2:e27.
    1. Van Damme L, Govinden R, Mirembe FM, Geudou F, Solomon S, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359:463–472.
    1. CONRAD. Phase III Trials of Cellulose Sulfate Microbicide for HIV Prevention Closed. Press Release. 2007. Available: . Accessed 31 January 2008.
    1. Rosenberg MJ, Davidson AJ, Chen JH, Judson FN, Douglas JM. Barrier contraceptives and sexually transmitted diseases in women: a comparison of female-dependent methods and condoms. Am J Public Health. 1992;82:669–674.
    1. Magder LS, Harrison HR, Ehret JM, Anderson TS, Judson FN. Factors related to genital Chlamydia trachomatis and its diagnosis by culture in a sexually transmitted disease clinic. Am J Epidemiol. 1988;128:298–308.
    1. Kelaghan J, Rubin GL, Ory HW, Layde PM. Barrier-method contraceptives and pelvic inflammatory disease. JAMA. 1982;248:184–187.
    1. Keith L, Berer GS, Moss W. Cervical gonorrhea in women using different methods of contraception. J Am Vener Dis Assoc. 1976;3:17–19.
    1. Moench TR, Chipato T, Padian NS. Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices. AIDS. 2001;15:1595–1602.
    1. Van Der Pol B, Martin DH, Schachter J, Quinn TC, Gaydos CA, et al. Enhancing the specificity of the COBAS AMPLICOR CT/NG test for Neisseria gonorrhoeae by retesting specimens with equivocal results. Journal of Clinical Microbiology. 2001;39:3092–3098.
    1. Diggle D, Heagerty P, Liang KY, Zeger S. Analysis of longitudinal data. Oxford University Press; 2002.
    1. Luchters S, Chersich MF, Jao I, Schroth A, Chidagaya A, et al. Acceptability of the diaphragm in Mombasa Kenya: A 6-month prospective study. Eur J Contracept Reprod Health Care. 2007;12:345–353.
    1. Behets F, Van Damme K, Turner AN, Rabenja NL, Ravelomanana NL, et al. Evidence-Based Planning of a Randomized Controlled Trial on Diaphragm Use for Prevention of Sexually Tranmsitted Infections. Sexually Transmitted Diseases. 2008;35:238–242.
    1. Grosskurth H, Mosha F, Todd J, Mwijarubi F, Klokke A, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: Randomized controlled trial. Lancet. 1995;346:530–536.
    1. Wawer MJ, Sewankambo NK, Serwadda D, Quinn TC, Paxton LA, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: A randomised community trial. Lancet. 1999;353:525–535.
    1. Kamali A, Quigley M, Nakiyinji J, Kinsman J, Kengeya-Kayondo J, et al. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: A community randomised trial. Lancet. 2003;361:645–652.
    1. Gregson S, Adamson S, Papaya S, Mundondo J, Nyamukapa CA, et al. Impact and process evaluation of integrated community and clinic-based HIV-1 control: A cluster-randomised trial in eastern Zimbabwe. PLoS Med. 2007;4:e102.
    1. Kaul R, Kimani J, Nagelkerke NI, Fonck K, Ngugi EN, et al. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers. JAMA. 2004;291:2555–2562.
    1. Gray RH, Wabwire-Mangen F, Kigozi G, Sewankambo NK, Serwadda D, et al. Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. Amj Obstet Gynecol. 2001;185:1209–1217.
    1. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med. 2008;358:1560–1571.
    1. Celum C, Wald A, Hughes J, Sanchez J, Reid S, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:2109–2119.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner